FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 32350104

Estimated average burden
hours per 0.5
response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Garfield Greg Shaw		2. Date of Event Requiring Statement (Month/Day/Year) 04/20/2021 3. Issuer Name and Ticker or Trading Symbol NeuroPace Inc [NPCE]								
(Last) (First) (Mi 368 EAST CAMPBELL AVI	ddle)	Issuer (Check all applicable)		Amendment, Date of Original (Month/Day/Year)						
SUITE 200			X Director Officer (give title below)		Owner (specify	(Che	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting			
(Street) CAMPBELL CA 95	008		title below)	below)	X	Person	by More than One		
(City) (State) (Zip))									
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Ins 4)	str. Form: (D) or			4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock			25,618	I		See Footnote ⁽¹⁾				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Ins	2. Date Exerting Expiration (Month/Da		3. Title and Amount of S Underlying Derivative S (Instr. 4)		4. Convers or Exerc	cise	5. 6. Nature of Indirect Beneficial Ownership Cownership (Instr.			
	Date Exercisabl	Expiration e Date	Title	Amount or Number of Shares	Derivativ Security	ve	Direct (D) or Indirect (I) (Instr. 5)	5)		
Series A' Preferred Stock	(2)	(2)	Common Stock	324,450	0.00)	I	See Footnote ⁽³⁾⁽⁴⁾		
Series B' Preferred Stock	(2)	(2)	Common Stock	5,289,934	0.00)	I	See Footnote ⁽⁵⁾⁽⁶⁾		

Explanation of Responses:

- 1. KCK Ltd. has sole voting and investment power with respect to the shares. The board of directors of KCK Ltd., consisting of Antoine Sacy, Kamal Kassar, and Nael Karim Kassar, has delegated its authority to vote or invest the shares to Nael Karim Kassar. As such, Nael Karim Kassar may also be deemed to have sole voting and investment with respect to the shares. Mr. Kassar and Greg Garfield, who serves as Senior Managing Director with KCK-US, Inc., an affiliate of KCK Ltd., are also members of our board of directors.
- 2. Each share of Preferred Stock automatically converts on a 1-for-1 basis into Common Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date.
- 3. Includes 859 shares of Series A' Preferred Stock held by the Greg and Dori Garfield Living Revocable Trust.
- 4. Includes 323,591 shares of Series A' Preferred Stock held by KCK Ltd. who has sole voting and investment power with respect to the shares. The board of directors of KCK Ltd., consisting of Antoine Sacy, Kamal Kassar, and Nael Karim Kassar, has delegated its authority to vote or invest the shares to Nael Karim Kassar. As such, Nael Karim Kassar may also be deemed to have sole voting and investment with respect to the shares. Mr. Kassar and Greg Garfield, who serves as Senior Managing Director with KCK-US, Inc., an affiliate of KCK Ltd., are also members of our board of directors.
- 5. Includes 5,271,902 shares of Series B' Preferred Stock held by KCK Ltd. who has sole voting and investment power with respect to the shares. The board of directors of KCK Ltd., consisting of Antoine Sacy, Kamal Kassar, and Nael Karim Kassar, has delegated its authority to vote or invest the shares to Nael Karim Kassar. As such, Nael Karim Kassar may also be deemed to have sole voting and investment with respect to the shares. Mr. Kassar and Greg Garfield, who serves as Senior Managing Director with KCK-US, Inc., an affiliate of KCK Ltd., are also members of our board of directors.
- 6. Includes 18,032 shares of Series B' Preferred Stock held by the Greg and Dori Garfield Living Revocable Trust.

Remarks:

<u>/s/ Mark B. Weeks,</u> <u>Attorney-in-Fact</u>

04/20/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints Michael Favet of NeuroPace, Inc. and Mark Weeks, Seth Gottlieb, Ryan James, Felipe Campos Lara Pereira, Kris Peardon, Debbie Wilkins, and Emma Levine Sporer of Cooley LLP, or any of them signing singly, with full power of substitution, the undersigned true and lawful attorney in fact to:

(1) execute for and on behalf of the undersigned, in the undersigned capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of NeuroPace, Inc. (the "Company"), Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;

(2)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute such Forms 3, 4 or 5 or Form ID (including any amendments thereto) and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-facts discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-facts substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the

earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Cooley LLP.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 6th day of April, 2021.

/s/	Greg	Garfield	

Greg Garfield